Floatz logo

Therapeutic Asset Ratings

278 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Azacitidine
Recurrent Adult Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (68)
Benadryl
Recurrent Adult Diffuse Large Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (68)
Fludarabine
Indolent Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (68)
PREDNISONE TABLETS
Recurrent Adult Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (68)
Cyclophosphamide
Indolent Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (68)
CIS-DIAMMINEDICHLOROPLATINUM II
Diffuse Large B-cell Lymphoma Recurrent
Institute of Hematology & Blood Diseases Hospital, ChinaP2/3BB (68)
Mitoxantrone
Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaP4BB (67)
Blinatumomab
Acute Lymphoblastic Leukemia, Pediatric
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (67)
Blinatumomab
ALL, Adult
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (67)
Blinatumomab
Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (67)
Benadryl
Recurrent Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (67)
Benadryl
Waldenström Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (67)
Dasatinib
Acute Lymphoblastic Leukemia, Pediatric
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (66)
Dasatinib
Recurrent Childhood Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (66)
Olverembatinib
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (66)
Venetoclax
AML, Adult
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (66)
Cyclophosphamide
Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (66)
Tislelizumab
Acute Myeloid Leukemia, in Relapsed or Refractory
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (66)
Tislelizumab
Acute Myeloid Leukemia With Positive Minimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (66)
Obinutuzumab
Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP4BB (65)
Pcc
Inhibitors
Institute of Hematology & Blood Diseases Hospital, ChinaP4BB (65)
Mosunetuzumab
Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (65)
Benadryl
Recurrent Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (65)
DARATUMUMAB
Acquired Hemophilia
Institute of Hematology & Blood Diseases Hospital, ChinaP4BB (64)
DARATUMUMAB
Hemophilia A With Inhibitor
Institute of Hematology & Blood Diseases Hospital, ChinaP4BB (64)
Showing 26 to 50 of 278 assets
PreviousPage 2 of 12Next